KR100510812B1 - 비용종 치료에서 H+, K+-ATPase 저해제의 용도 - Google Patents

비용종 치료에서 H+, K+-ATPase 저해제의 용도 Download PDF

Info

Publication number
KR100510812B1
KR100510812B1 KR10-1999-7003115A KR19997003115A KR100510812B1 KR 100510812 B1 KR100510812 B1 KR 100510812B1 KR 19997003115 A KR19997003115 A KR 19997003115A KR 100510812 B1 KR100510812 B1 KR 100510812B1
Authority
KR
South Korea
Prior art keywords
delete delete
alkyl
hydrogen
formula
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1999-7003115A
Other languages
English (en)
Korean (ko)
Other versions
KR20000049046A (ko
Inventor
페르 린드베르크
요안 피나스-마쏘
요르디 세라-카레라스
얀 트로파스트
Original Assignee
아스트라제네카 악티에볼라그
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 악티에볼라그 filed Critical 아스트라제네카 악티에볼라그
Publication of KR20000049046A publication Critical patent/KR20000049046A/ko
Application granted granted Critical
Publication of KR100510812B1 publication Critical patent/KR100510812B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
KR10-1999-7003115A 1996-10-11 1997-10-01 비용종 치료에서 H+, K+-ATPase 저해제의 용도 Expired - Fee Related KR100510812B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9603725-4 1996-10-11
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment

Publications (2)

Publication Number Publication Date
KR20000049046A KR20000049046A (ko) 2000-07-25
KR100510812B1 true KR100510812B1 (ko) 2005-08-31

Family

ID=20404214

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7003115A Expired - Fee Related KR100510812B1 (ko) 1996-10-11 1997-10-01 비용종 치료에서 H+, K+-ATPase 저해제의 용도

Country Status (33)

Country Link
EP (1) EP0946175B1 (cg-RX-API-DMAC7.html)
JP (1) JP4100713B2 (cg-RX-API-DMAC7.html)
KR (1) KR100510812B1 (cg-RX-API-DMAC7.html)
CN (1) CN1146416C (cg-RX-API-DMAC7.html)
AR (1) AR008886A1 (cg-RX-API-DMAC7.html)
AT (1) ATE230597T1 (cg-RX-API-DMAC7.html)
AU (1) AU738310B2 (cg-RX-API-DMAC7.html)
BR (1) BR9711896A (cg-RX-API-DMAC7.html)
CA (1) CA2268305C (cg-RX-API-DMAC7.html)
CZ (1) CZ298799B6 (cg-RX-API-DMAC7.html)
DE (1) DE69718347T2 (cg-RX-API-DMAC7.html)
DK (1) DK0946175T3 (cg-RX-API-DMAC7.html)
EE (1) EE04043B1 (cg-RX-API-DMAC7.html)
ES (1) ES2188995T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0000036A3 (cg-RX-API-DMAC7.html)
ID (1) ID23692A (cg-RX-API-DMAC7.html)
IL (1) IL129324A0 (cg-RX-API-DMAC7.html)
IS (1) IS1930B (cg-RX-API-DMAC7.html)
MY (1) MY117918A (cg-RX-API-DMAC7.html)
NO (1) NO321007B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ334786A (cg-RX-API-DMAC7.html)
PL (1) PL190902B1 (cg-RX-API-DMAC7.html)
PT (1) PT946175E (cg-RX-API-DMAC7.html)
RS (1) RS49599B (cg-RX-API-DMAC7.html)
RU (1) RU2197966C2 (cg-RX-API-DMAC7.html)
SA (1) SA97180641B1 (cg-RX-API-DMAC7.html)
SE (1) SE9603725D0 (cg-RX-API-DMAC7.html)
SK (1) SK284252B6 (cg-RX-API-DMAC7.html)
TR (1) TR199900770T2 (cg-RX-API-DMAC7.html)
TW (1) TW568784B (cg-RX-API-DMAC7.html)
UA (1) UA59374C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998016228A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA978842B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
EP1119349B1 (en) 1998-08-18 2008-07-02 The Regents Of The University Of California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
NZ514442A (en) * 1999-03-03 2003-08-29 Optinose As Nasal delivery device
WO2003043614A2 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
WO2003075926A1 (en) * 2002-03-14 2003-09-18 Altana Pharma Ag Use of proton pump inhibitors for the treatment of airway disorders
NZ536918A (en) * 2002-05-07 2006-09-29 Altana Pharma Ag Combination of pantoprazole and a respiratory agent for the treatment of respiratory diseases
WO2003094967A2 (en) * 2002-05-07 2003-11-20 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005025578A1 (en) 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
RU2252025C1 (ru) * 2003-11-28 2005-05-20 Дальневосточный государственный медицинский университет Способ лечения избыточной грануляционной ткани гортани и трахеи
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN104408249B (zh) * 2014-11-24 2017-09-26 广州供电局有限公司 单芯电缆导体热性参数的确定方法及系统
KR101974504B1 (ko) * 2017-04-10 2019-05-03 재단법인 아산사회복지재단 호산구성 비용종 동물모델

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate

Also Published As

Publication number Publication date
SK38499A3 (en) 2000-03-13
ES2188995T3 (es) 2003-07-01
PL332692A1 (en) 1999-09-27
MY117918A (en) 2004-08-30
CZ122999A3 (cs) 1999-09-15
BR9711896A (pt) 1999-08-24
UA59374C2 (uk) 2003-09-15
NO991619L (no) 1999-04-06
CN1146416C (zh) 2004-04-21
DK0946175T3 (da) 2003-03-17
WO1998016228A1 (en) 1998-04-23
ATE230597T1 (de) 2003-01-15
CA2268305C (en) 2006-11-28
ZA978842B (en) 1998-04-14
SK284252B6 (sk) 2004-12-01
DE69718347T2 (de) 2003-08-28
HUP0000036A3 (en) 2003-02-28
JP4100713B2 (ja) 2008-06-11
NZ334786A (en) 2000-12-22
EP0946175A1 (en) 1999-10-06
JP2001508034A (ja) 2001-06-19
IS5021A (is) 1999-04-08
PL190902B1 (pl) 2006-02-28
CN1232397A (zh) 1999-10-20
RU2197966C2 (ru) 2003-02-10
YU16399A (sh) 2000-03-21
CA2268305A1 (en) 1998-04-23
SA97180641B1 (ar) 2005-12-18
NO991619D0 (no) 1999-04-06
AU4640997A (en) 1998-05-11
AR008886A1 (es) 2000-02-23
DE69718347D1 (de) 2003-02-13
PT946175E (pt) 2003-04-30
HUP0000036A2 (hu) 2002-05-29
IL129324A0 (en) 2000-02-17
CZ298799B6 (cs) 2008-02-06
HU0000036D0 (cg-RX-API-DMAC7.html) 2002-05-29
ID23692A (id) 2000-05-11
KR20000049046A (ko) 2000-07-25
IS1930B (is) 2004-05-18
TW568784B (en) 2004-01-01
NO321007B1 (no) 2006-02-27
EE04043B1 (et) 2003-06-16
AU738310B2 (en) 2001-09-13
EE9900118A (et) 1999-10-15
HK1022848A1 (en) 2000-08-25
RS49599B (sr) 2007-06-04
SE9603725D0 (sv) 1996-10-11
EP0946175B1 (en) 2003-01-08
TR199900770T2 (xx) 1999-06-21

Similar Documents

Publication Publication Date Title
KR20000049046A (ko) 비용종 치료에서 H+, K+-ATPase 저해제의 용도
US6380222B2 (en) Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
IL157921A0 (en) Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
KR20010052721A (ko) 급성 천식 질환의 예방 또는 치료를 위한 포르모테롤 및부데소니드를 포함하는 조성물의 용도
JP2008110991A (ja) 処置方法
AU731274B2 (en) Anticancer composition comprising a diaminotrifluoromethylpyridine derivative
HK1022848B (en) Use of a combination of h+, k+ -atpase inhibitors and glucocorticoids in the treatment of nasal polyps
KR20180035840A (ko) S1p 수용체 조절제를 포함하는 조성물
US9636350B2 (en) Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid
CN1748695A (zh) 治疗鼻息肉和鼻息肉病的阿苯达唑鼻腔凝胶剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20080820

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20080820

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000